Tumor Necrosis Factor-alpha Activation of the c-Jun N-terminal Kinase Pathway in Human Neutrophils

INTEGRIN INVOLVEMENT IN A PATHWAY LEADING FROM CYTOPLASMIC TYROSINE KINASES TO APOPTOSIS*

Natalie J. AvdiDagger , Jerry A. NickDagger §, Ben B. Whitlock, Marcella A. BillstromDagger , Peter M. Henson||, Gary L. Johnson||**Dagger Dagger , and G. Scott WorthenDagger §**§§

From the Dagger  Department of Medicine,  Department of Pediatrics, || Program in Cell Biology, and ** Program in Molecular Signal Transduction, National Jewish Medical and Research Center and the § Departments of Medicine and Dagger Dagger  Pharmacology, University of Colorado School of Medicine, Denver, Colorado 80206

Received for publication, August 17, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The intensity and duration of an inflammatory response depends on the balance of factors that favor perpetuation versus resolution. At sites of inflammation, neutrophils adherent to other cells or matrix components are exposed to tumor necrosis factor-alpha (TNFalpha ). Although TNFalpha has been implicated in induction of pro-inflammatory responses, it may also inhibit the intensity of neutrophilic inflammation by promoting apoptosis. Since TNFalpha is not only an important activator of the stress-induced pathways leading to p38 MAPk and c-Jun N-terminal kinase (JNK) but also a potent effector of apoptosis, we investigated the effects of TNFalpha on the JNK pathway in adherent human neutrophils and the potential involvement of this pathway in neutrophil apoptosis. Stimulation with TNFalpha was found to result in beta 2 integrin-mediated activation of the cytoplasmic tyrosine kinases Pyk2 and Syk, and activation of a three-part MAPk module composed of MEKK1, MKK7, and/or MKK4 and JNK1. JNK activation was attenuated by blocking antibodies to beta 2 integrins, the tyrosine kinase inhibitors, genistein, and tyrphostin A9, a Pyk2-specific inhibitor, and piceatannol, a Syk-specific inhibitor. Exposure of adherent neutrophils to TNFalpha led to the rapid onset of apoptosis that was demonstrated by augmented annexin V binding and caspase-3 cleavage. TNFalpha -induced increases in annexin V binding to neutrophils were attenuated by blocking antibodies to beta 2 integrins, and the caspase-3 cleavage was attenuated by tyrphostin A9. Hence, exposure of adherent neutrophils to TNFalpha leads to utilization of the JNK-signaling pathways that may contribute to diverse functional responses including induction of apoptosis and subsequent resolution of the inflammatory response.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The rapid influx of polymorphonuclear leukocytes (neutrophils) into sites of injury is an important component of the acute inflammatory response in humans (1). The resulting adherence and chemotaxis of leukocytes in the appropriate cytokine milieu are not only necessary for efficient clearance of microorganisms (2) but may also participate in appropriate resolution of the inflammatory response through the subsequent induction of cell death by apoptosis.

Tumor necrosis factor-alpha (TNFalpha ),1 a pluripotent cytokine, is produced by a variety of leukocytes in response to stimulation by lipopolysaccharide (3). In turn, exposure to TNFalpha induces wide ranging biological effects including cell differentiation, proliferation, apoptosis, and multiple pro-inflammatory effects. TNFalpha exerts potent effects on neutrophils that have been suggested to contribute to the inflammatory response in sepsis (4, 5) and the adult respiratory distress syndrome (6). However, TNFalpha also exerts anti-inflammatory effects as demonstrated by an enhanced inflammatory response in TNFalpha -/- mice after infection (7), an effect that has been ascribed to the ability of TNFalpha to induce apoptosis in neutrophils (8).

Whereas TNFalpha can prime neutrophils in suspension (9, 10), many TNFalpha -induced cellular responses, including oxidant release, have been reported in association with beta 2-mediated, integrin-mediated adherence (11-13). Neutrophils utilize a variety of adhesion molecules (14), but studies employing either genetically manipulated mice (15), antibody blocking studies (16), and studies with adhesion molecule-deficient patients (17) have shown that integrins, in particular beta 2 and beta 3, are fundamentally important in adhesive events (16, 18). Integrin ligation in neutrophils results in reorganization of the cytoskeleton, cell spreading across an adhesive surface, and release of O2- and granule constituents.

Activation of tyrosine kinases plays a central role in human neutrophil integrin signaling (14). Studies have linked adherence-associated neutrophil responses in TNFalpha -stimulated neutrophils to beta 2 integrin-dependent phosphorylation of tyrosine kinase substrates and augmentation of p58c-Fgr and p53/56Lyn kinase activity (19-22). In addition, neutrophils induced to spread over fibrinogen in the presence of TNFalpha show integrin-dependent activation of Syk (a non-Src-like cytoplasmic) protein tyrosine kinase (PTK) which associates with p58c-Fgr and p53/56Lyn in co-localized complexes. The TNFalpha -induced phosphorylation of another tyrosine kinase, Pyk2, has also observed (23).

Recent studies have identified the integrin-associated cytoplasmic tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2 (24)), also known as CAKbeta -(cell adhesion kinase beta  (25)), RAFTK-(related adhesion focal tyrosine kinase (26)), CADTK-calcium-dependent tyrosine kinase CADTK (27)), as a member of the FAK family. Pyk2 has been identified in brain cells, cell lines and hematopoietic cells (24, 25, 28, 29). Studies in adherent neutrophils exposed to TNFalpha demonstrate that tyrosine phosphorylation of Pyk2 is beta 2 integrin-dependent and that Pyk2 appears to lie downstream of Lyn, Syk, protein kinase C, and reorganization of the cytoskeleton (30). Furthermore, overexpression of Pyk2 in PC12 cells, which have been stimulated with TNFalpha , induces JNK activation in a calcium-independent manner (31). Thus the altered response of the adherent neutrophil to TNFalpha may reflect in part differences in tyrosine kinase signaling through beta 2 integrin-mediated mechanisms.

Three distinct MAPk families have been described to date that may act downstream of tyrosine kinases. The prototypical p42/p44 ERK MAPk are activated in response to growth factors and chemoattractants, whereas the p38 MAPk and c-Jun N-terminal kinase (JNK) families modulate stress-activated responses (32, 33). Each MAPk cascade requires sequential activation of a MAPk kinase kinase (or equivalent) which can then activate a MAPk kinase, resulting in turn in the phosphorylation and activation of a MAPk (34, 35). In the neutrophil, only the p38 MAPk cascade has been clearly shown to be utilized in response to TNFalpha stimulation (36). Involvement of the p42/p44 ERK MAPk pathway in response to TNFalpha is controversial. Activation of a JNK pathway in the neutrophil has not as yet been shown in any context. Furthermore, regulation of apoptosis may represent a functional consequence of JNK, and this has yet to be delineated in the context of the neutrophil inflammatory response.

Apoptosis is an important mechanism for regulating the extent of an inflammatory response, making it self-limiting and thus preventing massive tissue damage. TNFalpha is a potent inducer of apoptosis in neutrophils, but its mechanisms of action are unknown. Recent reports have suggested that TNFalpha in conjunction with beta 2 integrins induces apoptosis in a tyrosine kinase-dependent manner (37), whereas other studies have shown activation of the cysteine proteases, caspase-3 and -8 (8). The role of MAPK members, in particular JNK pathway activation, in the TNFalpha induction of apoptosis remains controversial (38, 39).

The present study was undertaken to determine the conditions under which TNFalpha might activate the JNK pathway in human neutrophils, to define components of a putative MAPK-module, and to delineate key upstream components, as well as downstream functional consequences (in particular apoptosis). We report that in adherent neutrophils, activation of JNK1 in response to TNFalpha results from the mobilization of an integrin-mediated cascade involving activation of tyrosine kinases, in particular Syk and Pyk2, and activation of a MAPk module in which MEKK1 activates either or both of the MAPk kinases, MKK7 and MKK4. Among possible functional consequences of this pathway, we show that TNFalpha -elicited JNK activation is accompanied by a dramatic acceleration of neutrophil apoptosis which is modulated both by integrins and tyrosine kinases. Together, these results provide the first description to date of the activation of the JNK MAPk cascade in the human neutrophil, while providing a potential mechanism for TNFalpha -induced apoptosis in the human neutrophil.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Endotoxin-free reagents and plasticware were used throughout the experimental process. Neutrophils, prepared by previously described methods (40), were resuspended in Krebs-Ringer phosphate buffer, pH 7.2, with 0.2% dextrose (5% dextrose in 0.2% NaCl, injectable, Abbott) KRPD. KRPD salts were purchased from Mallinckrodt Chemical Works, and all components were diluted in endotoxin-free saline (0.9% saline for irrigation, Abbott). Aprotinin, leupeptin, PMSF, bovine serum albumin fraction V, sodium orthovanadate (Na3VO4), p-nitrophenyl phosphate (pNPP), Brij 97, protein A-Sepharose, wortmannin, and propidium iodide were purchased from Sigma. Recombinant human TNFalpha was from PharMingen (San Diego, CA). Genistein was purchased from Life Technologies, Inc., and piceatannol, tyrphostin A9, and tyrphostin A63 were from Calbiochem. Human serum albumin was from Intergen (Purchase, NY). NBD-phallacidin was from Molecular Probes (Eugene, OR). ECL reagents and [gamma -32P]ATP were from Amersham Pharmacia Biotech.

Antibodies and Protein Fragments-- Anti-JNK1 (C-17), phosphospecific anti-JNK (G-7), anti-MEKK (C-22), anti-Syk (C-20), anti-MKK7 (T-19), and c-Jun-(1-79) were all from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-Lyn was from Transduction Laboratories (San Diego, CA). Anti-MKK4 and anti-caspase-3 were purchased from PharMingen, and the phosphospecific anti-SEK1 was from New England Biolabs (Beverly, MA). Anti-CR3 receptor (anti-CD11b) was purchased from Dako (Denmark). Mouse IgG was from Upstate Biotechnology Inc. (Lake Placid, CA). Anti-CD11b F(ab')2 fragments were generated with an Immunopure IgG1 F(ab) and F(ab')2 Preparation kit, using immobilized ficin (Pierce).

Histidine-tagged Recombinant Proteins-- Wild type SEK1 (SEK1wt), wild type JNK1 (JNK1wt), and kinase-inactive JNK1 (JNK1km) were expressed in Escherichia coli and purified as described previously (40).

Preincubation of Neutrophils to Promote Adherence-- Neutrophils were resuspended at 20 × 106/ml in complete KRPD containing 0.25% human serum albumin, 1 mM PMSF, 10 µg/ml leupeptin, and 10 µg/ml aprotinin. Following this, 20 × 106 cells were either preincubated in a tube under static conditions for 55 min at 37 °C (cell-cell/homotypic adherence; hereafter referred to as adherent neutrophils) or preincubated in a tube under static conditions for 30 min at 37 °C and then aliquoted into 1 well of a 12-well plate (cell-substratum adherence) for an additional 25 min prior to stimulation with 10 ng/ml TNFalpha for the intervals indicated hereafter. Cells were either harvested from wells into a microcentrifuge tube and pelleted at 15,000 rpm for 20 s or those stimulated in microcentrifuge tubes were directly pelleted.

JNK1 Immunoprecipitation-- Cell pellets were lysed with 500 µl of cold JNK lysis buffer, JLB (50 mM Tris, pH 7.5, 10% glycerol, 1% Nonidet P-40, 137 mM NaCl, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM PMSF, 2 mM NaF, 1 mM Na3VO4) and centrifuged at 15,000 rpm for 10 min at 4 °C. Triton-soluble cell lysates were precleared with protein A-Sepharose for 15 min, 4 °C, prior to immunoprecipitation with anti-JNK1 for 2 h at 4 °C.

JNK1 in Vitro Kinase Assay-- Beads were washed once in JNK lysis buffer and twice in JNK reaction mix (20 mM beta -glycerophosphate, pH 7.2, 50 mM Hepes, pH 7.6, 50 µM Na3VO4, 1 mM dithiothreitol, 10 mM MgCl2, 12 mM pNPP). 40 µl of in vitro kinase assay mix containing 10 µCi of [32P]ATP and 500 ng of c-Jun-(1-79) in JNK reaction mix were added to samples that were incubated for 30 min at 30 °C. Reactions were terminated with addition of 5× Laemmli sample buffer, subjected to SDS-PAGE, and proteins transferred to nitrocellulose. c-Jun-(1-79) phosphorylation was quantified by PhosphorImager (Molecular Dynamics) analysis and visualized by autoradiography.

JNK activity was expressed as a ratio percentage of unstimulated control (% BL). Baseline-BL.

MKK4/MKK7 in Vitro Kinase Assays-- Adherent neutrophils were exposed to TNFalpha , lysed in JNK lysis buffer, and immunoprecipitated with either anti-MKK4 or anti-MKK7. MKK4-bound beads or MKK7-bound beads were then washed once in JNK lysis buffer and twice in JNK reaction mix. For direct in vitro kinase assays, samples were incubated with 40 µl of JNK reaction mix containing 10 µCi of [gamma -32P]ATP and 500 ng of JNK1km for 30 min at 30 °C. For coupled in vitro kinase assays, samples, immunoprecipitated and washed as above, were incubated with 40 µl of JNK reaction mix containing 10 µCi of [gamma -32P]ATP, 250 µM ATP, 50 ng JNK1wt, and 500 ng of c-Jun-(1-79) for 30 min at 30 °C. All reactions were terminated with the addition of 5× Laemmli sample buffer, subjected to SDS-PAGE, and proteins transferred to nitrocellulose. Phosphorylation of substrates (JNK1km, c-Jun-(1-79), and JNK1wt) was quantified by PhosphorImager (Molecular Dynamics) analysis and visualized by autoradiography.

MEKK1-coupled in Vitro Kinase Assay-- Adherent neutrophils were stimulated with TNFalpha , pelleted, lysed in RIPA buffer (50 mM Tris, pH 7.2, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10 mM sodium pyrophosphate, 25 mM beta -glycerophosphate, 1 mM Na3VO4, and 2.1 µg/ml aprotinin), and immunoprecipitated with anti-MEKK1. MEKK1-bound protein A-Sepharose beads were washed once in RIPA, once in PAN (10 mM Pipes pH 7.0, 100 mM NaCl, 21 µg/ml aprotinin), and then incubated with 48 µl of the MEKK in vitro kinase mix (25 mM beta -glycerophosphate, pH 7.2, 20 mM Hepes, pH 7.6, 100 µM Na3VO4, 2 mM dithiothreitol, 20 mM MgCl2, and 100 µM ATP) containing 10 ng of SEK1wt and 100 ng of JNK1wt for 10 min at 30 °C. 2 µl of a mix containing 15 µCi of [gamma -32P]ATP and 500 ng of c-Jun-(1-79) were added to the samples which were further incubated for 30 min at 30 °C. Reactions were terminated with the addition of 5× Laemmli sample buffer, and proteins were separated by SDS-PAGE. Phosphorylation of JNK1wt and c-Jun-(1-79) was quantified by PhosphorImager analysis and visualized by autoradiography.

Syk/Lyn in Vitro Kinase Autophosphorylation Studies-- Adherent neutrophils were stimulated with TNFalpha and lysed in Syk lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Brij 97, 1 mM Na3VO4, 10 µg/ml leupeptin, and 10 µg/ml aprotinin). Brij-soluble lysates were protein A-Sepharose immunoprecipitated with either anti-Syk or anti-Lyn. Syk-bound beads or Lyn-bound beads were washed twice in wash buffer A (25 mM Hepes, pH 7.5, 150 mM NaCl, 0.1% Brij 97, 1 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml leupeptin) and twice in wash buffer B (25 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM NaVO4, 10 µg/ml aprotinin, and 10 µg/ml leupeptin). Beads and kinase mix (25 mM Hepes, pH 7.5, 2 mM MnCl2, 20 mM pNPP, and 25 µCi of [gamma -32P[ATP]) were preincubated separately for 5 min at 30 °C and then 40 µl of kinase mix added to beads for 1 min at 30 °C. The reaction was terminated with 5× Laemmli sample buffer. Samples were boiled for 5 min at 100 °C, subjected to SDS-PAGE, and transferred to nitrocellulose by immunoblotting. Autophosphorylation was detected and quantified by PhosphorImager Analysis.

Inhibitor Studies-- Neutrophils were preincubated with the PI3-kinase inhibitor wortmannin and tyrosine kinase inhibitor genistein as described (40, 41). 10 and 30 µM piceatannol were used for Syk and Lyn in vitro kinase autophosphorylation studies. Neutrophils were preincubated with tyrphostin A9 (5 µM) or tyrphostin A63 (50 µM) a negative control, for 1 h at 37 °C prior to stimulation with TNFalpha .

Apoptosis Assessment-- For annexin V binding, externalized phosphatidylserine was determined by annexin V binding. Adherent neutrophils were exposed to TNFalpha for 1, 1.5, and 2 h. Aliquots containing 2.5 × 105 cells were resuspended in 100 µl of NBD buffer, pH 7.5 (137 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 5 mM glucose, 10 mM Hepes, and 2.5 mM CaCl2), incubated with 400 ng of annexin V fluorescein (Caltag Laboratories, Burligame, CA) and 500 ng of propidium iodide for 15 min at room temperature and placed on ice with the addition of 400 µl of cold NBD buffer. FACs analysis was performed by flow cytometry on a FACScan (Becton Dickinson), and annexin V binding was determined from the non-necrotic cell population, which stains negatively for propidium iodide. 5000 cells were analyzed in each sample. For caspase-3 cleavage, 20 × 106 adherent neutrophils were exposed to TNFalpha , 10 ng/ml for 0, 1, 1.5, and 2 h. Cells were lysed in RIPA, and whole cell lysates were prepared from the Triton-soluble fraction. Samples were subjected to SDS-PAGE using a 14% gel, and proteins were transferred to nitrocellulose membrane that was then probed with antibodies to caspase-3 by Western blot analysis.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

TNFalpha Activates JNK in Adherent Neutrophils-- Adherent human neutrophils were stimulated with TNFalpha , and JNK1 was immunoprecipitated from Triton-soluble cell lysates, and JNK activation was measured by the phosphorylation of an N-terminal fragment of c-Jun (c-Jun-(1-79)) in the presence of [32P]ATP. Phosphorylation of c-Jun-(1-79) by JNK1 immunoprecipitates was augmented following TNFalpha stimulation of neutrophils (Fig. 1A). Activation was detected at 5 min and was maximal between 10 and 15 min. Immunoblots, probed with anti-JNK1 antibody, confirmed that equivalent amounts of JNK were immunoprecipitated and that in neutrophils the predominant immunoreactive JNK1 species is a 55-kDa protein (Fig. 1C). A change in the electrophoretic mobility of JNK1, consistent with phosphorylation, was detected as early as 1 min after TNFalpha exposure. JNK1 activation was further supported by immunodetection with a phosphospecific anti-JNK1 antibody, indicating increased phosphorylation of JNK in the Triton-soluble fraction of JNK1 immunoprecipitates 5 min after TNFalpha stimulation of neutrophils (Fig. 1B). The time course of JNK1 phosphorylation mirrored the phosphorylation of c-Jun-(1-79).



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   TNFalpha -stimulated activation of JNK. A, autoradiograph depicting the time course of activation of JNK1. JNK was immunoprecipitated with anti-JNK1 from the lysates of neutrophils, exposed to TNFalpha (10 ng/ml for 1, 5, 10, 15, and 30 min) or buffer (30 min) and subjected to in vitro kinase assay using c-Jun-(1-79) as a substrate. Samples were separated on SDS-PAGE and transferred to nitrocellulose. The phosphorylated c-Jun-(1-79) is visualized in the autoradiograph. B, anti-phosphospecific JNK immunoblot of Triton-soluble whole cell lysates (WCL) from neutrophils, stimulated with TNFalpha (10 ng/ml) for 1, 5, 10, 15, and 30 min. C, anti-JNK1 immunoblot of TNFalpha -stimulated adherent neutrophils (10 ng/ml for 1, 5, 10, 15, and 30 min). Anti-JNK1 immunoprecipitates were subjected to SDS-PAGE and transferred to nitrocellulose. Membranes were probed with anti-JNK-1 (B, buffer). Figure depicts a representative result from three consecutive experiments.

The Role of Adherence in JNK Activation-- JNK activation was studied in neutrophils preincubated under different conditions that promote adherence and then exposed to TNFalpha . Cells were maintained either stationary in a tube under conditions that favor cell-cell interactions or stimulated on a surface, favoring cell-substratum interactions (Fig. 2A). Neutrophil exposure to TNFalpha induced comparable amounts of JNK1 activation under both sets of conditions (Fig. 2B). Since integrins, in particular beta 2 and beta 3, are important components of neutrophil-adhesive interactions, we questioned whether beta 2 integrins were up-regulated by TNFalpha on the neutrophil surface. Neutrophils, exposed to TNFalpha for various time intervals, were stained with anti-CD11b, an antibody directed against beta 2 integrins, and their fluorescence was analyzed by flow cytometry. We observed a time-dependent up-regulation of beta 2 integrins on the neutrophil surface in those cells that had been exposed to TNFalpha (Fig. 2C).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Role of adherence in JNK activation. A, autoradiograph depicting JNK activity under two conditions that promote adherence. Phosphorylation of the substrate c-Jun-(1-79) was determined by JNK in vitro kinase assay on JNK1 immunoprecipitates from neutrophils preincubated in one of two ways: (i) under stationary conditions in a test tube for 55 min (cell-cell adherence); or (ii) in a tube for 30 min and then plated in a well for 25 min (cell substratum). Following preincubation cells were stimulated with TNFalpha (10 ng/ml for 15 min), lysed, and immunoprecipitated with anti-JNK. B, buffer and T, TNFalpha . B, graph represents mean c-Jun-(1-79) phosphorylation ± S.E. from PhosphorImager analyses of phosphorylated c-Jun-(1-79) band under the conditions described above. By using the Student t test, we determined a lack of statistically significant differences in JNK activation. C, graph depicts TNFalpha -induced up-regulation of CD11b. Neutrophils, exposed to TNFalpha (10 ng/ml) for 15, 30, and 60 min or buffer and stained with anti-CD11b, were analyzed by fluorescence analysis on the FACScan (Becton Dickinson) for surface expression of CD11b. CD11b up-regulation was expressed as a relative fluorescence index (RFI), (, buffer; black-square, TNFalpha ).

beta 2 Integrin Dependence of JNK Activation-- Previous studies have indicated a role for integrins in mediating a variety of neutrophil responses, including the activity of the Na/H+ antiport and oxygen radical release (12, 42). To determine whether the TNFalpha -induced JNK activation we had observed was beta 2 integrin-mediated, neutrophils were pretreated with a blocking antibody directed against CD11b, prior to TNFalpha stimulation, and JNK activity was determined on JNK immunoprecipitates. The resultant JNK activation was significantly diminished compared with controls (Fig. 3, A and B).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   beta 2 integrin involvement in JNK activation. A, autoradiograph showing JNK activation following preincubation with anti-CD11b. Neutrophils were pretreated with either buffer (-), isotype control antibody, mouse IgG 20 µg/ml (IgG), or the beta 2 integrin blocking antibody, anti-CD11b10 µg/ml, 20 µg/m,(CD11b) for 55 min at 37 °C, stimulated with buffer (B) or TNFalpha (T, 1 ng/ml for 15 min). JNK activity was determined on JNK immunoprecipitates by in vitro kinase assay, in which c-Jun-(1-79) was used as substrate. Samples were separated by SDS-PAGE, transferred to nitrocellulose, and the phosphorylated c-Jun-(1-79) visualized by autoradiography. B, graph depicting JNK activity under the same conditions demonstrated in A. JNK activation was determined from c-Jun-(1-79) phosphorylation by the protocol described for samples from (Fig. 2A) and was quantified by PhosphorImager analysis. The graph depicts mean JNK activity ± S.E. of three experiments. Statistical analysis employing a one-way ANOVA determined that in the presence of 20 µg/ml anti-CD11b, JNK activation was significantly reduced compared with control, * (p < 0.01). C, graph depicts TNFalpha -induced increase in actin assembly in the absence and presence of anti-CD11b. Neutrophils were pretreated in the absence () and presence (black-square) of anti-CD11b (10 µg/ml), stimulated with TNFalpha (10 ng/ml) for 0, 2, 5, and 15 min, and then stained with NBD-phallacidin. The fluorescence was analyzed by flow cytometry on an Epics (Coulter) for determination of actin assembly as described previously (45).

To validate the specificity of blocking by anti-CD11b, two types of control experiments were performed. The first, using mouse IgG as an isotype-matched antibody, ruled out the possibility that the inhibition observed was due to anti-CD11b competition for protein A-Sepharose (preventing anti-JNK1 binding), whereas it also tested the blocking capabilities of anti-CD11b per se (Fig. 3, A and B). The second, carried out to determine whether anti-CD11b inhibited the TNFR and thus its downstream signaling, examined a TNFalpha -induced function, actin assembly. We have previously shown in neutrophils and HL-60 promyelocytic cells, stimulated with either chemoattractants or lipopolysaccharide, that actin assembly is differentiable from integrin-mediated adherence (43-45). Neutrophils, pretreated in the absence and presence of anti-CD11b and stimulated with TNFalpha , demonstrated identical actin assembly in both cases (Fig. 3C), indicating that anti-CD11b does not modulate the TNFR or its immediate downstream signaling.

MKK7 and MKK4 Activate JNK1-- Whereas JNK activation has been reported as a consequence of MKK4/SEK1 activation in many cell systems (46), the recent description of MKK7 (homologous to hemipterous, the Drosophila JNK kinase) (47) as a downstream effector of TNFalpha suggests its potential role (48). Activation of MKK4 and MKK7 following TNFalpha exposure was determined in MKK4 and MKK7 immunoprecipitates by direct phosphorylation of a kinase-inactive recombinant human JNK1 (JNK1km). A time-dependent increase in JNK1km phosphorylation by both MKK4 and MKK7 immunoprecipitates from TNFalpha -stimulated neutrophils was detected (Fig. 4A). To determine whether the JNK1km phosphorylation induced by MKK4 and MKK7 resulted in enhanced activation of JNK1, we determined whether these MKK homologues could initiate a coupled reaction leading to c-Jun-(1-79) via kinase-active JNK1. Both MKK4 and MKK7 immunoprecipitates from TNFalpha -exposed neutrophils induced phosphorylation of the JNK1wt and c-Jun-(1-79) substrates with a time course identical to that shown for JNK1km (Fig. 4B). However, MKK7 induced much stronger phosphorylation than did MKK4. Immunodetection of immunoprecipitated MKK4 and MKK7 confirmed that within each experiment, equivalent amounts of each kinase were immunoprecipitated (data not shown). Since MKK4 appeared to be only a weak activator of JNK1, we further verified that MKK4 itself was being activated by probing with an antibody specific for the phosphorylated (active) form of MKK4. MKK4 was activated in a time-dependent manner in TNFalpha -stimulated neutrophils (Fig. 4C). Immunoblotting the same samples with an antibody to MKK4 confirmed that equivalent amounts of MKK4 had been immunoprecipitated.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   TNFalpha activates MKK4 and MKK7. A, MKK4/MKK7 direct in vitro kinase assay. Autoradiograph of JNKkm phosphorylated directly by either MKK4 or MKK7 immunoprecipitates from neutrophils stimulated with TNFalpha (10 ng/ml) for 0, 5, 10, and 15 min is shown. B, autoradiograph of coupled MKK4/MKK7 activation assays. MKK4 and MKK7 immunoprecipitates from neutrophils, stimulated with TNFalpha (10 ng/ml) for 0, 5, 10 and 15 min, and then subjected to in vitro kinase assay (30 min, at 30 °C) using JNKwt and c-Jun-(1-79) as substrates are shown. Phosphorylated proteins were separated by SDS-PAGE, transferred to nitrocellulose, and visualized by PhosphorImager analysis. C, anti-MKK4 immunoblots from neutrophils exposed to TNFalpha (10 ng/ml) for 5 and 15 min. Triton-soluble lysates were immunoprecipitated with anti-MKK4, subjected to SDS-PAGE, and transferred to nitrocellulose. Membranes were probed with either anti-phosphospecific MKK4 or anti-MKK4.

TNFalpha Induces MEKK1 Activation-- MAP kinase kinase kinases reported to activate MKK4 include MLK, MEKK1, and MEKK4 (49-51). Since it has been shown that MEKK1 activates JNK1 in TNFalpha -stimulated macrophages (52), we employed a coupled assay to determine whether MEKK1 activity was induced in neutrophils by TNFalpha exposure. MEKK1 immunoprecipitates were incubated together with the kinase-active (wild type) recombinant human kinase substrates MKK4 and JNK1 and a c-Jun fragment, c-Jun-(1-79). The consequence of this coupled co-incubation is visualized in a representative autoradiograph (Fig. 5A) wherein increased phosphorylation of both the c-Jun-(1-79) and JNK1wt species was detected, peaking 5 min after TNFalpha stimulation of adherent neutrophils. The time course of MEKK1 activity, determined from several experiments, was quantified from c-Jun-(1-79) phosphorylation (Fig. 5B). MEKK1 activation peaked 5 min after TNFalpha stimulation of neutrophils and declined to a plateau between 10 and 15 min. Phosphorylation of wild type recombinant JNK1 was also detected, confirming that JNK1 is itself a substrate for recombinant MKK4 following MEKK1 activation in neutrophils.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   TNFalpha activates MEKK1 in neutrophils. A, autoradiograph showing time course of MEKK1 activation. Neutrophils were stimulated with TNFalpha (10 ng/ml) for 0, 5, 10, and 15 min. MEKK1 immunoprecipitates from Triton-soluble lysates were subjected to coupled in vitro kinase assay using MKK4wt, JNK1wt, and c-Jun-(1-79) as substrates. Samples were separated by SDS-PAGE, transferred to nitrocellulose, and phosphorylated JNK1wt and c-Jun-(1-79) visualized. B, MEKK1 time course. Above samples were subjected to PhosphorImager analysis, and phosphorylation of band representing c-Jun-(1-79) was quantified. Graph depicts mean c-Jun-(1-79) phosphorylation ± S.E. for 3 consecutive experiments. C, autoradiograph displaying beta 2 integrin-associated MEKK1 activity. Neutrophils, pretreated in the absence (-) or presence (+) of anti-CD11b (10 µg/ml), were exposed to TNFalpha (10 ng/ml) for 5 min, and lysates were immunoprecipitated with anti-MEKK1. Immunoprecipitates were subjected to coupled in vitro kinase assay as described under "Experimental Procedures." Samples were subjected to SDS-PAGE and transferred to nitrocellulose. Phosphorylated c-Jun-(1-79) and JNKwt were visualized by autoradiography (B, buffer and T, TNFalpha ).

By having determined the TNFalpha -stimulated JNK1 activation in neutrophils to be beta 2 integrin-dependent, we next questioned whether integrin input into the signaling pathway leading to JNK1 activation might occur upstream from MEKK1 or between MEKK1 and JNK1. MEKK activity was determined in response to TNFalpha in the presence and absence of anti-CD11b by a coupled in vitro kinase assay. MEKK1 immunoprecipitates were prepared from neutrophils, pretreated in the absence and presence of anti-CD11b, and then exposed to TNFalpha . The phosphorylation of c-Jun-(1-79) and JNK1wt induced by these immunoprecipitates is shown (Fig. 5C). We observed greatly decreased phosphorylation of both the c-Jun-(1-79) and JNK1wt species in TNFalpha -stimulated neutrophils that had been pretreated with anti-CD11b, suggesting that the integrin-dependent activation of JNK occurs at, or upstream of, MEKK1.

Involvement of Tyrosine Kinases in the beta 2 Integrin-mediated JNK Activation-- Since studies in adherent neutrophils exposed to TNFalpha have shown that phosphorylation and activation of tyrosine kinases are associated with integrin activation, we sought to determine whether tyrosine kinases were involved in the TNFalpha -induced JNK activation in adherent neutrophils. Activation of JNK1 from TNFalpha -stimulated neutrophils was assessed following pretreatment with genistein, an inhibitor of tyrosine kinases, and wortmannin, a PI3-kinase inhibitor. TNFalpha -induced JNK activation was significantly inhibited in cells that had been pretreated with genistein but unaffected by wortmannin (Fig. 6). Since the Src family kinase member, Lyn, and the non-Src cytoplasmic tyrosine kinase, Syk, have been implicated in the stress-activated JNK pathway in B-cells (53-56) and in integrin signaling in platelets (57) and monocytes (58), we questioned whether either kinase was activated in adherent neutrophils exposed to TNFalpha and, if so, whether this activation contributed to JNK pathway activation in the neutrophil.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of genistein (tyrosine kinase inhibitor) and wortmannin (PI3-kinase inhibitor on JNK1 activation. Neutrophils, pretreated with either genistein (100 µM), wortmannin (50 nM), or 0.1% Me2SO control for 55 min were stimulated with TNFalpha (10 ng/ml) for 15 min. JNK activity was determined on JNK1 immunoprecipitates by in vitro kinase assay using c-Jun-(1-79) as substrate. Samples were separated by SDS-PAGE, transferred to nitrocellulose, and analyzed by PhosphorImager analysis. Graph depicts mean phosphorylated c-Jun-(1-79) ± S.E. Statistical analysis employing a one-way ANOVA determined that in presence of genistein for JNK activation was significantly reduced compared with control, * (p < 0.001), whereas there no significant difference with wortmannin.

In initial studies, the tyrosine kinase activities of Syk and Lyn were determined in vitro by autophosphorylation. Anti-Syk immunoprecipitates from TNFalpha -stimulated adherent neutrophils exhibited tyrosine kinase activity with greatly enhanced autophosphorylation of a 40-kDa species, consistent with the almost universal proteolytic cleavage product of Syk (59) (Fig. 7A). Incubation with piceatannol, a Syk-specific inhibitor (60), inhibited this autophosphorylation in a dose-dependent fashion. In contrast to the augmented Syk activation, we observed minimal activation of the Src family kinase, Lyn, in TNFalpha -stimulated adherent neutrophils (Fig. 7B). Additionally, the autophosphorylation activity of immunoprecipitated Lyn was diminished only slightly at the highest concentration of piceatannol.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 7.   TNFalpha -induced Syk activation and beta 2 integrin association. A, autoradiograph of TNFalpha -induced Syk autophosphorylation and its inhibition in the presence of piceatannol. Neutrophils were stimulated with either buffer (-) or TNFalpha (+), 10 ng/ml for 5 min, and Syk immunoprecipitates were subjected to in vitro kinase assay in the presence of 0.1% Me2SO (solvent control), piceatannol (10 or 30 µM). Samples were subjected to SDS-PAGE, transferred to nitrocellulose, and the autophosphorylated p40Syk visualized by PhosphorImager analysis. B, autoradiograph depicting Lyn activity in TNFalpha -stimulated (10 ng/ml, 5 min) adherent neutrophils. P53/56Lyn autophosphorylation was determined on anti-Lyn immunoprecipitates in presence of 0.1% Me2SO, piceatannol (10 or 30 µM). C, beta 2 integrin-associated inhibition of Syk autophosphorylation. Neutrophils were pretreated with anti-CD11b (10 µg/ml for 55 min) exposed to TNFalpha (10 ng/ml) for 5 min, and an in vitro kinase assay was performed on the anti-Syk immunoprecipitates. Samples were subjected to SDS-PAGE, transferred to nitrocellulose, and the Syk autophosphorylation visualized (B, buffer and T, TNFalpha ).

Since integrin signaling may proceed through Syk activation (19), we next questioned whether Syk activation in TNFalpha -stimulated neutrophils was also integrin-dependent. The Syk autophosphorylation activity, determined on Syk immunoprecipitates, was diminished by preincubation of neutrophils with anti-CD11b antibody prior to TNFalpha exposure (Fig. 7C). This observation provided a link between beta 2 integrins and Syk activation in our system, raising the possibility that Syk may be a component of the integrin-signaling pathway leading to JNK1 activation.

To test this hypothesis, we studied the effects of a Syk-specific inhibitor, piceatannol, on the TNFalpha -induced activation of MEKK1 and JNK1 in adherent neutrophils. Piceatannol pretreatment of TNFalpha -stimulated neutrophils resulted in reduced MEKK1 activation (Fig. 8A) as determined by the diminished phosphorylation of both the c-Jun-(1-79) and JNK1wt species. Similarly, piceatannol pretreatment induced a concentrationdependent inhibition of JNK1 activation in TNFalpha -stimulated neutrophils (Fig. 8B). Pretreatment of neutrophils with 10 µM piceatannol, a concentration that significantly inhibited Syk autophosphorylation but had no effect on Lyn autophosphorylation, decreased JNK1 activation by 66%.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   Syk involvement in JNK pathway activation. A, MEKK activation following piceatannol pretreatment. Neutrophils, preincubated in the absence (-) and presence (+) of piceatannol (30 µM), were stimulated with TNFalpha (10 ng/ml for 5 min), and anti-MEKK1 immunoprecipitates were exposed to coupled in vitro kinase assay (as described under "Experimental Procedures"). Samples were subjected to SDS-PAGE and transferred to nitrocellulose. Phosphorylated substrates were visualized by autoradiography (B, buffer and T, TNFalpha ). B, JNK activity following pretreatment with piceatannol. Neutrophils, pretreated with 0.1% Me2SO (control) or piceatannol (3, 10, 30, and 100 µM) for 55 min, were stimulated in the absence (Delta ) or presence of TNFalpha (black-triangle), 10 ng/ml, for 15 min. JNK1 immunoprecipitates were subjected to in vitro kinase assay using c-Jun-(1-79) as substrate, and samples separated by SDS-PAGE were transferred to nitrocellulose. Phosphorylated c-Jun-(1-79) was quantified by PhosphorImager analysis. Graph represents mean c-Jun phosphorylation ± S.E. of three consecutive experiments.

Recent studies have linked activation of another tyrosine kinase, Pyk2, a FAK family member, to TNFalpha -induced JNK signaling in PC12 cells (31), whereas beta 2 integrin-mediated Pyk2 phosphorylation in adherent neutrophils, exposed to TNFalpha (23) has been also shown. Furthermore, in the latter system, Pyk2 has been shown to lie downstream of Syk and Lyn (30). Hence, we questioned whether Pyk2 was phosphorylated under our experimental conditions and, if so, was this linked to the JNK activation we had observed earlier. Enhanced tyrosine phosphorylation of Pyk2 was detected in Pyk2 immunoprecipitates from TNFalpha -stimulated neutrophils compared with the unstimulated controls (Fig. 9A). Tyrphostin A9, a tyrosine kinase inhibitor, has been shown to inhibit specifically Pyk2 phosphorylation in TNFalpha -stimulated neutrophils (23). Adherent neutrophils, pretreated with tyrphostin A9 and stimulated with TNFalpha , exhibited reduction in JNK activation compared with nonpretreated controls (Fig. 9B).



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 9.   TNFalpha -induced Pyk2 activation and association with the JNK pathway. A, Western blot analysis of tyrosine-phosphorylated Pyk2. Neutrophils, stimulated with either buffer (B) or TNFalpha (T), 10 ng/ml, for for 5 and 15 min were immunoprecipitated (IP) with anti-Pyk2. Samples, separated by SDS-PAGE, were transferred to nitrocellulose and membranes probed with anti-phosphotyrosine. B, autoradiography showing dose response of tyrphostin A9 inhibition on JNK activation. Neutrophils, pretreated with piceatannol (10 µM), tyrphostin A9 (1 µM, 5 µM), or solvent control (0.1% Me2SO) were either stimulated with either buffer (B) or TNFalpha (T), 10 ng/ml, for 15 min. A JNK in vitro kinase assay was performed on JNK1 immunoprecipitates, and the phosphorylation of a c-Jun-(1-79) fragment substrate was visualized by PhosphorImager analysis.

TNFalpha -induced Apoptosis in Adherent Neutrophils-- Exposure to TNFalpha induces apoptosis in many cells by mechanisms that, while controversial, may involve the JNK pathway. Annexin V binding and caspase-3 cleavage were used to examine the onset of apoptosis in human neutrophils. Annexin V binding to neutrophils, studied at 1, 1.5, and 2 h post-TNFalpha stimulation was significantly increased at 1.5 and 2 h post-TNFalpha (Fig. 10A). Pretreatment of neutrophils with anti-CD11b F(ab')2 fragments prior to TNFalpha stimulation attenuated this increase that was significant at 2 h post-TNFalpha . The onset of nuclear condensation, as determined from cytospin preparations, and the susceptibility of this process to anti-CD11b fragments were similar to annexin V binding (data not shown).



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 10.   TNFalpha -induced apoptosis. A, effect of anti-CD11b on TNFalpha -induced annexin V binding. Unstimulated neutrophils () or neutrophils exposed to TNFalpha (10 ng/ml, for 1, 1.5, and 2 h) in the absence (black-square) and presence (black-triangle) of anti-CD11b F(ab')2 fragments (2 µg/ml) were incubated with a mixture of annexin V fluorescein and propidium iodide, and their fluorescence was analyzed by flow cytometry. (10,000 cells were analyzed, and the percent of cells binding annexin V was determined from the propidium iodide-negative staining population.) Graph represents mean annexin V binding ± S.E. of three experiments. Statistical analysis was carried out by two-way ANOVA. * designates comparison of (i) TNFalpha /buffer with p < 0.0136 at 1.5 h and p < 0.0001 for 2 h and (ii) TNFalpha -CD11b/buffer with p < 0.002. ** represents (p < 0.01) for samples stimulated with TNFalpha for 2 h in the presence and absence of anti-CD11b F(ab')2 fragments. B, TNFalpha induces caspase-3 cleavage in neutrophils. Anti-caspase-3 immunoblot shows the appearance of the 17-kDa cleavage product with time. Triton-soluble lysates were prepared from neutrophils stimulated with either buffer (B) or TNFalpha (T) 10 ng/ml for 0, 60, 90, and 120 min. Samples were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-caspase-3. The 32-kDa proenzyme is cleaved into a heterodimer of 17-21 and 12 kDa. In neutrophils we have only observed the 17-kDa species. C, immunoblot showing the effect of tyrphostin A9 on caspase-3 cleavage. Neutrophils were preincubated in the absence (-) or presence of 5 µM tyrphostin A9 (+) prior to stimulation with buffer (B) or TNFalpha (T), 10 ng/ml, for 1, 1.5, and 2 h. Triton-soluble lysates were prepared, and samples separated by SDS-PAGE were transferred to nitrocellulose and probed with anti-caspase-3 by Western blotting.

Caspase-3 cleavage has been widely described in cells undergoing apoptosis, including neutrophils. We observed a time-dependent cleavage of pro-caspase-3 (32 kDa) to a caspase-3 cleavage product (17 kDa) in lysates from adherent neutrophils that had been exposed to TNFalpha (Fig. 10B). When neutrophils were preincubated with tyrphostin A9 (the Pyk2-associated tyrosine kinase inhibitor shown in Fig. 9B to inhibit JNK activation) and then stimulated with TNFalpha , the cleavage of caspase-3 was greatly reduced (Fig. 10C).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Regulation of cellular responses to specific stimuli occurs in part through selective activation of MAPk-signaling cascades. In human neutrophils, chemoattractant-induced activation of c-Raf and MEKK1 leads to the activation of p42/p44 ERK MAPk pathways (40, 41, 61, 62), whereas chemoattractants and lipopolysaccharide activate p38 MAPk as well (63, 64). In contrast, studies to date in human neutrophils have not as yet provided evidence for activation of JNK and its associated signaling partners. This study, performed in primary human neutrophils, describes key elements leading to activation of the JNK pathway following stimulation with TNFalpha under adherent conditions. Our data support the conclusion that integration of two signals, one from integrin-mediated adherence and the other through the TNF receptor(s), regulates a pathway in which activation of tyrosine kinases, Syk and Pyk2, is linked to activation of a MAPK module consisting of MEKK1, MKK4/7, JNK1, and associated with cleavage of caspases-3 and externalization of phosphatidylserine (Fig. 11). We propose that induction of apoptosis, a critical mechanism for maintaining a self-limiting inflammatory response, may be associated with activation of these elements. This pathway not only constitutes the first report of activation and utilization of a JNK pathway in human neutrophils but joins a very limited group of studies on apoptosis induced through stimulation of the JNK pathway.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 11.   Proposed scheme for activation of JNK pathway in TNFalpha -stimulated adherent neutrophils. TNFalpha -stimulated activation of JNK1 proceeds through TNFR and beta 2 integrin-mediated activation of the Syk and Pyk2 tyrosine kinases, MEKK1 and MKK4/MKK7. Functional outcomes of JNK1 activation may be associated with induction of apoptosis.

JNK activation in response to TNFalpha exposure has been reported for a variety of cell types (65). Ten different human JNK isoforms, found as either 46- or 55-kDa proteins, have been described, arising from the alternative splicing of the three genes jnk1, jnk2, and jnk3. We detected by Western blot analysis both the 46- and 55-kDa species, although the predominant species was a 55-kDa protein. This p55 splice variant we detected is probably JNK1alpha 2 or JNK1beta 2 (65, 66). Evidence of TNFalpha -induced neutrophil JNK activation comes both from observations that immunoprecipitated, endogenous JNK is itself specifically phosphorylated following TNFalpha stimulation and that it phosphorylates a c-Jun fragment substrate.

The MAP kinases kinases reported to be directly upstream of JNK include MKK4 and the recently cloned MKK7 (67). Overexpression of MKK4 in a variety of cell types leads to activation of JNK(s) (46, 68), and its targeted deletion blocks the activation of JNK in embryonic fibroblasts (69). Recent studies, however, suggest that MKK7 may be the preferred MKK leading to JNK activation following TNFalpha exposure (48). In our studies, both MKK4 and MKK7 were activated in a stimulus-dependent manner when neutrophils were exposed to TNFalpha , indicating the likelihood that both MKK4 and MKK7 are involved in JNK1 activation in the neutrophil. Our data, while suggesting that MKK7 may be a more potent activator of JNK1 than MKK4 in this system, do not preclude the possibility that immunoprecipitation may not allow detection of the full extent of activation. In keeping with the upstream location of MKK4 and MKK7, their peak activation (5 min) precedes that of JNK1 (10-15 min). Similar time courses of activation for JNK and MKK4 have been reported in macrophages following TNFalpha exposure (52).

MAP kinase kinase kinases shown to act upstream of JNK include MEKK family members (49, 50, 70, 71), MLK3 (72), ASK-1 (51), and NIK (73). We have focused on MEKK1, which phosphorylates and activates MKK4 in vitro (49). Overexpression of MEKK1 in a variety of cell types results in activation of both MKK4 and JNK(s) (49, 74) and also leads to apoptosis in fibroblasts (75). In this study, we demonstrate, with the use of recombinant constituents of the JNK pathway, MEKK1 activation in adherent neutrophils following exposure to TNFalpha . In light of our previous findings that formyl-methionyl-leucyl-phenylalanine induces MEKK1-associated p42/44 ERK MAPk activation (conditions in which MKK4 is not activated (40)), we speculate that the neutrophil may respond to specific stimuli by using the same upstream kinase but allowing different downstream effectors to be activated. The yeast accomplishes such specificity through the use of scaffolding proteins (76). Additionally, or alternatively, other MEKK family members may also activate MKK4 and MKK7 in response to TNFalpha .

Signaling events upstream of MEKK remain to be elucidated, although the pleiotropic actions of TNFalpha (7) are known to be mediated by two TNF receptors, RI and RII, that belong to a superfamily of cell surface receptors including Fas and CD40 (77). Although most of the biological effects of TNFalpha are ascribed to TNFRI (78, 79), neutrophils express both types.2 Binding of TNFalpha induces receptor aggregation and recruitment of TNFR-associated proteins (80-82), including TRAF2 and RIP, thought to be points of divergence that lead to many downstream events, including activation of the JNK pathway and of the transcription factor NF-kappa B (83).

In spite of the many activities linked to activation of TNFRI and -II, we demonstrate that an additional component, neutrophil adherence, is necessary for JNK1 activation in TNFalpha -stimulated neutrophils. Although neutrophils utilize a variety of adhesion molecules, beta 2 integrins are fundamentally important in both homotypic and cell-substratum adhesive events, and neutrophil interactions with the extracellular matrix have been shown to require integrins (16). In our studies, both the JNK and MEKK1 activation in TNFalpha -stimulated adherent neutrophils could be blocked by pretreatment of cells with an antibody to CD11b, the alpha  subunit of the beta 2 integrin, Mac-1 (CD11b/CD18, aMbeta 2). Although JNK activation following integrin activation alone has been reported (84), we found that in neutrophils adherence in the absence of TNFalpha stimulation was insufficient to initiate activation of JNK1. By using an isotype control antibody, we demonstrated that the anti-Cd11b blocking was indeed specific. Additionally, we present evidence that anti-CD11b does not block the TNFR itself by demonstrating that TNFalpha -induced actin assembly in neutrophils is an integrin-independent function (Fig. 2C). Initial actin assembly in the neutrophil in response to variety of agonists occurs in suspension and is independent of beta 2 integrin blockade. Hence, this provides a system in which integrin-independent signaling events downstream of the TNFR and its expression can be assessed.

Neutrophil interactions with the extracellular matrix have been shown to induce phosphorylation of specific cytoplasmic tyrosine kinases, including the Src family member p58Fgr (19-22). Fuortes and colleagues (20) have demonstrated that TNFalpha activation of adherent neutrophils resulted in tyrosine phosphorylation of several protein species that were not seen in suspended cells. Our studies show that the tyrosine kinase inhibitor, genistein, attenuated TNFalpha -induced JNK activation, providing initial evidence for upstream participation of tyrosine kinases. A recent study in T-cells reports that activation through the T-cell receptor, if associated with ligation of a co-receptor, results in activation of Syk and downstream activation of the JNK pathway (85), whereas Syk has also been reported to be associated with integrins (57, 58). We have not only demonstrated Syk activation, which could be inhibited by anti-CD11b antibodies, but also inhibition of both Syk and JNK activation by piceatannol, the Syk-specific inhibitor, thus linking Syk and JNK activation in neutrophil. Although we were unable to ascertain from our present studies clear involvement of the Src family member, Lyn, we feel that at present we cannot discount its contribution.

Recent studies, however, have shown that another tyrosine kinase, the FAK family Pyk2, localizes to podosomes and focal adhesion-type structures in TNFalpha -stimulated adherent neutrophils (23). TNFalpha -induced Pyk2 phosphorylation in neutrophils is decreased in the presence of beta 2 integrin blocking antibodies (30) and Pyk2 integrates signals from integrins and TNFR (23). In B-cells, aggregation of beta 1 integrins (86) and in T-cells, beta 3 integrins (87) results in the phosphorylation of Pyk2. Our studies in adherent neutrophils show both phosphorylation of immunoprecipitated Pyk2 following TNFalpha stimulation and inhibition of JNK activation by the tyrphostin A9, shown to inhibit specifically Pyk2 (23). These observations provide preliminary evidence that Pyk2 may be associated with JNK activation in the neutrophil and are in agreement with studies in which Pyk2 overexpression in 293 cells leads to activation of co-expressed JNK, whereas dominant-negative Pyk2 inhibits JNK in PC12 (31). Pyk2 has been linked to JNK via p130Cas and p130Crk (87, 88). Whereas in THP1 cells the PI3-kinase pathway is associated with Pyk2 (89), it is not necessary for Pyk2 activation in neutrophils (30). This observation agrees with our findings that wortmannin does not affect TNFalpha -induced JNK activation in neutrophils. Our studies on Syk and Pyk2, together with our CD11b blocking studies in TNFalpha -induced JNK activation in the neutrophil, further strengthen our hypothesis that the JNK pathway may require two interacting signals, one of which involves beta 2 integrins whose actions are mediated in part by activation of tyrosine kinases. However, the TNFR- and integrin-mediated signals may not necessarily be independent, since they may reflect the action by TNFalpha to modify integrin function (19) as demonstrated by both the capability of TNFalpha to induce up-regulation of CD18/CD11b (Fig. 3C) and stimulate beta 2 integrin-mediated adherence in neutrophils (90). Since both antibodies to beta 2 integrins and piceatannol inhibited MEKK1 activation (Fig. 5 and Fig. 8), these data indicate that protein tyrosine kinases and beta 2 integrins effects impinge on the JNK pathway upstream of MEKK1.

In the neutrophil, as in many other cells, TNFalpha enhances apoptosis. We have shown herein that in adherent neutrophils TNFalpha induces apoptosis with a rapid time course comparable to that induced by UV exposure (91). Whereas recent studies invoke a role for JNK as a co-participant of apoptosis in response to ionizing radiation, UV, TNFalpha (38), and trophic factor deprivation (92), the role of JNK in apoptosis may be stimulus- and cell-specific. Certain studies suggest the possibility that JNK lies upstream of caspase-3 (93). Our studies on caspase-3 cleavage and annexin V binding demonstrated the induction of apoptosis in TNFalpha -stimulated adherent neutrophils.

Walzog and colleagues (37) have previously suggested that integrin involvement is important in TNFalpha -induced apoptosis and, furthermore, that tyrosine kinase inhibitors modulate the induction of apoptosis. Similarly, it has been demonstrated that wound macrophages induce neutrophil apoptosis through a mechanism requiring both TNFalpha and integrin-ligand interactions (94). Of considerable interest, Coxon and colleagues (95) have reported that CD11b -/- mice exhibit an increase in elicited neutrophils, ascribed, in part, to a failure of apoptosis. Similarly, we found that preincubation of neutrophils with F(ab)'2 fragments of anti-CD11b partially inhibited annexin V binding. Furthermore, a recent report that overexpression of Pyk2 leads to apoptosis in rat and mouse fibroblasts (27) supports our studies in which caspase-3 cleavage is both attenuated and delayed following preincubation of neutrophils with tyrphostin A9. These effects on caspase-3 cleavage were induced by the same concentrations of tyrphostin A9 that inhibited JNK activation.

While TNFalpha alone is a potent inducer of apoptosis in transformed cells, an additional insult is required to induce apoptosis in normal cells (e.g. cycloheximide). We propose that in human neutrophils, integrin involvement is required to induce apoptosis in the presence of TNFalpha . Hence, unlike many cells, in which integrin-mediated detachment from substratum leads to apoptosis (anoikis), we have found, in contrast, that the neutrophil requires integrin-mediated attachment for apoptosis to occur. As we have previously reported, UV-induced apoptosis of neutrophils involves the MAP kinase family member p38 (91). Thus, neutrophil apoptosis may involve different MAP kinase family members for apoptotic responses under diverse conditions.

The acute inflammatory response is characterized both by large numbers of adherent neutrophils and the presence of TNFalpha . It is precisely these conditions, as we have demonstrated here, that allow the neutrophil to utilize the JNK pathway. The consequences of such activation including apoptosis may act to down-regulate the intensity of the inflammatory response. Although further studies, including investigations using genetically manipulated mice, are required to determine the relationship between the JNK pathway and apoptosis, this complex activation sequence provides a mechanism for enabling the neutrophil to both acquire specific functional capabilities and to ensure they are only used transiently.


    ACKNOWLEDGEMENTS

We thank Drs. D. W. Riches, E. D. Chan, S. C. Frasch, P. Gerwins, and K. C. Malcolm for helpful discussions and Dr. D. L. Bratton and D. A. Richter for advice on the annexin V binding assay. We also thank Leigh Landskroner and Barry Silverstein for assistance with illustrations and Brenda Sebern for assistance with the manuscript.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ Supported by National Institutes of Health Grants HL40784, HL61407, and HL13403. To whom correspondence should be addressed. Tel.: 303-398-1171; Fax: 303-398-1851; E-mail:worthens@njc.org.

Published, JBC Papers in Press, October 25, 2000, DOI 10.1074/jbc.M007527200

2 G. S. Worthen, N. J. Avdi, M. M. K. Gillespie, and P. E. Parsons, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: TNFalpha , tumor necrosis factor-alpha ; MAP, mitogen-activated protein; MAPk, MAP kinase; ERK, extracellular signal-regulated kinase; pNPP, p-nitrophenyl phosphate; MKK, MAPk/ERK kinase (MEK); MEKK, MEK kinase (MAPk kinase kinase); JNK, c-Jun N-terminal kinase; JNKwt, recombinant wild type JNK1; JNKkm, recombinant kinase-inactive JNK1; SEK, SAPK/ERK kinase; PI3-kinase, phosphatidylinositol 3-kinase; PAF, platelet-activating factor; Pyk2, Proline-rich tyrosine kinase 2; TNFR, TNF receptor; PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel electrophoresis; Pipes, 1,4-piperazinediethanesulfonic acid; ANOVA, analysis of variance; NBD, 12-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Henson, P. M., Tonnesen, M. G., Worthen, G. S., and Parsons, P. E. (1988) in Human Inflammatory Disease, Clinical Immunology (Maronne, G. , Lichtenstein, L. M. , Kondorelli, M. , and Fauci, A., eds), Vol. 1 , pp. 69-76, B. C. Decker, Inc., Toronto, Canada
2. Smith, J. A. (1994) J. Leukocyte Biol. 56, 672-686[Abstract]
3. Han, J., Brown, T., and Beutler, B. (1990) J. Exp. Med. 171, 465-475[Abstract]
4. Windsor, A. C., Walsh, C. J., Mullen, P. G., Cook, D. J., Fisher, B. J., Blocher, C. R., Leeper-Woodford, S. K., Sugerman, H. J., and Fowler, A. A. (1993) J. Clin. Invest. 91, 1459-1468
5. Windsor, A. C., Mullen, P. G., Walsh, C. J., Fisher, B. J., Blocher, C. R., Jesmok, G., Fowler, A. A., and Sugerman, H. J. (1994) Arch. Surg. 129, 80-89[Abstract]
6. Parsons, P. E., Moore, F. A., Moore, E. E., Iklé, D. N., Henson, P. M., and Worthen, G. S. (1992) Am. Rev. Respir. Dis. 146, 694-700[Medline] [Order article via Infotrieve]
7. Marino, M., Dunn, A., Grail, D., Inglese, M., Noguchi, Y., Richards, E., Jungbluth, A., Wada, H., Moore, M., Williamson, B., Basu, S., and Old, L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8093-8098[Abstract/Free Full Text]
8. Yamashita, K., Takahashi, A., Kobayashi, S., Hirata, H., Mesner, P. W., Jr., Kaufmann, S. H., Yonehara, S., Yamamoto, K., Uchiyama, T., and Sasada, M. (1999) Blood 93, 674-685[Abstract/Free Full Text]
9. Coffer, P. J., and Koenderman, L. (1997) Immunol. Lett. 57, 27-31[CrossRef][Medline] [Order article via Infotrieve]
10. Lloyds, D., Brindle, N. P., and Hallett, M. B. (1995) Immunology 84, 220-226[Medline] [Order article via Infotrieve]
11. Dapino, P., Dallegri, F., Ottonello, L., and Sacchetti, C. (1993) Clin. Exp. Immunol. 94, 533-538[Medline] [Order article via Infotrieve]
12. Nathan, C., and Sanchez, E. (1990) J. Cell Biol. 111, 2171-2181[Abstract]
13. Ottonello, L., Dapino, P., Scirocco, M., Barbera, P., and Dallegri, F. (1994) Agents Actions 41, 57-61[Medline] [Order article via Infotrieve]
14. Berton, G., and Lowell, C. A. (1999) Cell. Signal. 11, 621-635[CrossRef][Medline] [Order article via Infotrieve]
15. Lowell, C. A., Fumagalli, L., and Berton, G. (1996) J. Cell Biol. 133, 895-910[Abstract]
16. Nathan, C., Srimal, S., Farber, C., Sanchez, E., Kabbash, L., Asch, A., Gailit, J., and Wright, S. D. (1989) J. Cell Biol. 109, 1341-1349[Abstract]
17. Anderson, D. C., and Springer, T. A. (1987) Annu. Rev. Med. 38, 175-194
18. Lindberg, F. P., Bullard, D. C., Caver, T. E., Gresham, H. D., Beaudet, A. L., and Brown, E. J. (1996) Science 274, 795-798[Abstract/Free Full Text]
19. Berton, G., Fumagalli, L., Laudanna, C., and Sorio, C. (1994) J. Cell Biol. 126, 1111-1121[Abstract]
20. Fuortes, M., Jin, W. W., and Nathan, C. (1993) J. Cell Biol. 120, 777-784[Abstract]
21. Fuortes, M., Jin, W. W., and Nathan, C. (1994) J. Cell Biol. 127, 1477-1483[Abstract]
22. Yan, S. R., Fumagalli, L., Dusi, S., and Berton, G. (1995) J. Leukocyte Biol. 58, 595-606[Abstract]
23. Fuortes, M., Melchior, M., Han, H., Lyon, G. J., and Nathan, C. (1999) J. Clin. Invest. 104, 327-335[Abstract/Free Full Text]
24. Lev, S., Moreno, H., Martinez, R., Canoll, P., Peles, E., Musacchio, J. M., Plowman, G. D., Rudy, B., and Schlessinger, J. (1995) Nature 376, 737-745[CrossRef][Medline] [Order article via Infotrieve]
25. Sasaki, H., Nagura, K., Ishino, M., Tobioka, H., Kotani, K., and Sasaki, T. (1995) J. Biol. Chem. 270, 21206-21219[Abstract/Free Full Text]
26. Herzog, H., Nicholl, J., Hort, Y. J., Sutherland, G. R., and Shine, J. (1996) Genomics 32, 484-486[CrossRef][Medline] [Order article via Infotrieve]
27. Xiong, W., and Parsons, J. T. (1997) J. Cell Biol. 139, 529-539[Abstract/Free Full Text]
28. Abraham, E., Bursten, S., Shenkar, R., Albee, J., Tuder, R., Woodson, P., Guidot, D., Rice, G., Singer, J., and Repine, J. (1995) J. Exp. Med. 181, 569-575[Abstract]
29. Salgia, R., Avraham, S., Pisick, E., Li, J. L., Raja, S., Greenfield, E. A., Sattler, M., Avraham, H., and Griffin, J. D. (1996) J. Biol. Chem. 271, 31222-31226[Abstract/Free Full Text]
30. Yan, S. R., and Novak, M. J. (1999) FEBS Lett. 451, 33-38[CrossRef][Medline] [Order article via Infotrieve]
31. Tokiwa, G., Dikic, I., Lev, S., and Schlessinger, J. (1996) Science 273, 792-794[Abstract]
32. Blumer, K. J., and Johnson, G. L. (1994) Trends Biochem. Sci. 19, 236-240[CrossRef][Medline] [Order article via Infotrieve]
33. Levin, D. E., and Errede, B. (1995) Curr. Opin. Cell Biol. 7, 197-202[CrossRef][Medline] [Order article via Infotrieve]
34. Cooper, J. A. (1994) Curr. Biol. 4, 1118-1121[Medline] [Order article via Infotrieve]
35. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846[Free Full Text]
36. Nahas, N., Molski, T. F. P., Fernandez, G. A., and Sha'afi, R. I. (1996) Biochem. J. 318, 247-253[Medline] [Order article via Infotrieve]
37. Walzog, B., Jeblonski, F., Zakrzewicz, A., and Gaehtgens, P. (1997) FASEB J. 11, 1177-1186[Abstract/Free Full Text]
38. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. (1996) Nature 380, 75-79[CrossRef][Medline] [Order article via Infotrieve]
39. Natoli, G., Costanzo, A., Ianni, A., Templeton, D. J., Woodgett, J. R., Balsano, C., and Levrero, M. (1997) Science 275, 200-203[Abstract/Free Full Text]
40. Avdi, N., Winston, B. W., Russel, M., Young, S. K., Johnson, G. L., and Worthen, G. S. (1996) J. Biol. Chem. 271, 33598-33606[Abstract/Free Full Text]
41. Worthen, G. S., Avdi, N., Buhl, A. M., Suzuki, N., and Johnson, G. L. (1994) J. Clin. Invest. 94, 815-823
42. Nathan, C. F. (1989) Blood 73, 301-306[Abstract]
43. Worthen, G. S., Schwab, B., Elson, E. L., and Downey, G. P. (1989) Science 245, 183-185
44. Erzurum, S. C., Downey, G. P., Doherty, D. E., Schwab, B., III, Elson, E. L., and Worthen, G. S. (1992) J. Immunol. 149, 154-162[Abstract/Free Full Text]
45. Erzurum, S. C., Kus, C., Bohse, C., Elson, E. L., and Worthen, G. S. (1991) Am. J. Resp. Cell Mol. Biol. 5, 230-241
46. Lin, A., Minden, A., Martinetto, H., Claret, F.-X., Lange-Carter, C., Mercurio, F., Johnson, G. L., and Karin, M. (1995) Science 268, 286-290
47. Gavin, A. C., and Schorderet-Slatkine, S. (1997) Mol. Reprod. Dev. 46, 383-391[CrossRef][Medline] [Order article via Infotrieve]
48. Moriguchi, T., Toyoshima, F., Masuyama, N., Hanafusa, H., Gotsh, Y., and Nishida, E. (1997) EMBO J. 16, 7045-7053[Abstract/Free Full Text]
49. Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J., and Johnson, G. L. (1993) Science 260, 315-319
50. Gerwins, P., Blank, J., and Johnson, G. (1997) J. Biol. Chem. 272, 8288-8295[Abstract/Free Full Text]
51. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Science 275, 90-94[Abstract/Free Full Text]
52. Winston, B. W., Chan, E. D., Johnson, G. L., and Riches, D. W. (1997) J. Immunol. 159, 4491-4497[Abstract]
53. Cambier, J. C. (1995) J. Immunol. 155, 3281-3285
54. Cheng, A. M., Rowley, B., Pao, W., Hayday, A., Bowlen, J. B., and Pawson, T. (1995) Nature 378, 303-306[CrossRef][Medline] [Order article via Infotrieve]
55. Cheng, A. M., Negishi, I., Anderson, S. J., Chan, A. C., Bolen, J., Loh, D. Y., and Pawson, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9797-9801[Abstract/Free Full Text]
56. Clark, M. R., Campbell, K. S., Kazlauskas, A., Johnson, S. A., Hertz, M., Potter, T. A., Pleiman, C., and Cambier, J. C. (1992) Science 258, 123-126
57. Shattil, S. J., Ginsberg, M. H., and Brugge, J. S. (1994) Curr. Opin. Cell Biol. 6, 695-704[Medline] [Order article via Infotrieve]
58. Lin, T. H., Rosales, C., Mondal, K., Bolen, J. B., Haskill, S., and Juliano, R. L. (1995) J. Biol. Chem. 270, 16189-16197[Abstract/Free Full Text]
59. Taniguchi, T., Kobayashi, T., Kondo, J., Takahashi, K., Nakamura, H., Suzuki, J., Nagai, K., Yamada, T., Nakamura, S.-I., and Yamamura, H. (1991) J. Biol. Chem. 24, 15790-15796
60. Oliver, J. M., Burg, D. L., Wilson, B. S., McLaughlin, J. L., and Gaehlen, R. L. (1994) J. Biol. Chem. 269, 29697-29703[Abstract/Free Full Text]
61. Buhl, A. M., Avdi, N., Worthen, G. S., and Johnson, G. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9190-9194[Abstract]
62. Knall, C., Young, S., Nick, J. A., Buhl, A. M., Worthen, G. S., and Johnson, G. L. (1996) J. Biol. Chem. 271, 2832-2838[Abstract/Free Full Text]
63. Nick, J. A., Avdi, N. J., Gerwins, P. R., Johnson, G. L., and Worthen, G. S. (1996) J. Immunol. 156, 4867-4875[Abstract/Free Full Text]
64. Nick, J., Avdi, N., Young, S., Knall, C., Johnson, G., and Worthen, G. (1997) J. Clin. Invest. 99, 975-986[Abstract/Free Full Text]
65. Kyriakis, J., Banerjee, P., Nikolakaki, E., Dal, T., Rubie, E., Ahmad, M., Avruch, J., and Woodgett, J. (1994) Nature 369, 156-160[CrossRef][Medline] [Order article via Infotrieve]
66. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. (1996) EMBO J. 15, 2760-2770[Abstract]
67. Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T., and Davis, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7337-7342[Abstract/Free Full Text]
68. Dérijard, B., Raingeaud, J. L., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685
69. Yang, Tournier, C., Wysk, M., Lu, H., Xu, J., Davis, R., and Flavell, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3004-3009[Abstract/Free Full Text]
70. Blank, J., Gerwins, P., Elliot, E., Sather, S., and Johnson, G. (1996) J. Biol. Chem. 271, 5361-5368[Abstract/Free Full Text]
71. Fanger, G. R., Johnson, N. L., and Johnson, G. L. (1997) EMBO J. 16, 4961-4972[Abstract/Free Full Text]
72. Tibbles, L. A., Ing, Y. L., Kiefer, F., Chan, J., Iscove, N., Woodgett, J. R., and Lassam, N. J. (1996) EMBO J. 15, 7026-7035[Abstract]
73. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) Nature 385, 540-544[CrossRef][Medline] [Order article via Infotrieve]
74. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266, 1719-1723
75. Johnson, N. L., Gardner, A. M., Diener, K. M., Lange-Carter, C. A., Gleavy, J., Jarpe, M. B., Minden, A., Karin, M., Zon, L. I., and Johnson, G. L. (1996) J. Biol. Chem. 271, 3229-3237[Abstract/Free Full Text]
76. Yablonski, D., Marbach, I., and Levitzki, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13864-13869[Abstract/Free Full Text]
77. Cleveland, J. L., and Ihle, J. N. (1995) Cell 81, 479-483[Medline] [Order article via Infotrieve]
78. Mori, L., Iselin, S., De Libero, G., and Lesslauer, W. (1996) J. Immunol. 157, 3178-3182[Abstract]
79. Kondo, S., and Sauder, D. (1997) Eur. J. Immunol. 27, 1713-1718[Medline] [Order article via Infotrieve]
80. Yeh, W.-C., Shahinian, A., Speiser, D., Kraunus, J., Billia, F., and Wakeham, A. (1997) Immunity 7, 715-725[Medline] [Order article via Infotrieve]
81. Lee, S. Y., Lee, S. Y., and Choi, Y. (1997) J. Exp. Med. 185, 1275-1285[Abstract/Free Full Text]
82. Schievella, A. R., Chen, J. H., Graham, J. R., and Lin, L.-L. (1997) J. Biol. Chem. 272, 12069-12075[Abstract/Free Full Text]
83. Karin, M., and Delhause, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9067-9069[Free Full Text]
84. Miyamoto, S., Teramoto, H., Coso, O. A., Gutkind, S., Burbel, P. D., Akiyama, S. K., and Yamada, K. M. (1995) J. Cell Biol. 131, 791-805[Abstract]
85. Jacinto, E., Werlen, G., and Karin, M. (1998) Immunity 8, 31-41[Medline] [Order article via Infotrieve]
86. Ma, E. A., Lou, O., Berg, N. N., and Ostergaard, H. L. (1997) Eur. J. Immunol. 27, 329-335[Medline] [Order article via Infotrieve]
87. Astier, A., Avraham, H., Manie, S. N., Groopman, J., Canty, T., Avraham, S., and Freedman, A. S. (1997) J. Biol. Chem. 272, 228-232[Abstract/Free Full Text]
88. Blaukat, A., Ivankovic-Dikic, I., Gronroos, E., Dolfi, F., Tokiwa, G., Vuori, K., and Dikic, I. (1999) J. Biol. Chem. 274, 14893-14901[Abstract/Free Full Text]
89. Hatch, W. C., Ganju, R. K., Hiregowdara, D., Avraham, S., and Groopman, J. E. (1998) Blood 91, 3967-3973[Abstract/Free Full Text]
90. Berton, G., Yan, S. R., Fumagalli, L., and Lowell, C. A. (1996) Int. J. Clin. & Lab. Res. 26, 160-177[Medline] [Order article via Infotrieve]
91. Frasch, S. C., Nick, J. A., Fadok, V. A., Bratton, D. L., Worthen, G. S., and Henson, P. M. (1998) J. Biol. Chem. 273, 8389-8397[Abstract/Free Full Text]
92. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326-1331[Abstract]
93. Muhlenbeck, F., Haas, E., Schwenzer, R., Schubert, G., Grell, M., Smith, C., Scheurich, P., and Wajant, H. (1998) J. Biol. Chem. 273, 33091-33098[Abstract/Free Full Text]
94. Meszaros, A. J., Reichner, J. S., and Albina, J. E. (2000) J. Immunol. 165, 435-441[Abstract/Free Full Text]
95. Coxon, A., Rieu, P., Barkalow, F. J., Askari, S., Sharpe, A. H., von Andrian, U. H., Arnaout, M. A., and Mayadas, T. N. (1996) Immunity 5, 653-666[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.